0001209191-23-038686.txt : 20230621
0001209191-23-038686.hdr.sgml : 20230620
20230620214631
ACCESSION NUMBER: 0001209191-23-038686
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230615
FILED AS OF DATE: 20230620
DATE AS OF CHANGE: 20230620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MUNEY ALAN
CENTRAL INDEX KEY: 0001194497
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39289
FILM NUMBER: 231027299
MAIL ADDRESS:
STREET 1: 48 MONROE TURNPIKE
CITY: TRUMBULL
STATE: CT
ZIP: 06611
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cano Health, Inc.
CENTRAL INDEX KEY: 0001800682
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9725 NW 117TH AVENUE, SUITE 200
CITY: MIAMI
STATE: FL
ZIP: 33178
BUSINESS PHONE: 2034227700
MAIL ADDRESS:
STREET 1: 9725 NW 117TH AVENUE, SUITE 200
CITY: MIAMI
STATE: FL
ZIP: 33178
FORMER COMPANY:
FORMER CONFORMED NAME: Jaws Acquisition Corp.
DATE OF NAME CHANGE: 20200121
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-15
0
0001800682
Cano Health, Inc.
CANO
0001194497
MUNEY ALAN
C/O CANO HEALTH INC.
9725 NW 117TH AVENUE
MIAMI
FL
33178
1
0
0
0
0
Class A Common Stock
2023-06-15
4
A
0
185598
A
248500
D
These securities represent restricted stock units ("RSUs") granted under the Cano Health, Inc. 2021 Stock Option and Incentive Plan. Each unit represents a right to receive one share of the Issuer's Class A Common Stock. The RSUs vest on the earlier of (i) June 15, 2024 or (ii) the Issuer's next annual meeting of stockholders, in each case so long as the reporting person remains in service as a member of the board on such date. These RSUs have been awarded to the reporting person to fully satisfy the Issuer's 2023 total annual equity and cash compensation for non-employee directors. This amount includes RSUs received in lieu of the $50,000 cash portion of the reporting person's total annual compensation based on a price of $1.347 per share (based on the volume weighted average price of the Issuer stock over the twenty business days preceding the grant).
/s/ David J. Armstrong, Attorney-in-Fact
2023-06-20